In 2012, the European Medicines Agency (EMA) approved the first-ever AAV-based gene therapy Glybera [11], a recombinant AAV product that delivers the human lipoprotein lipase (LPL) gene to treat hereditary lipoprotein lipase deficiency (LPLD) [12]. The gene discussed is LPL; the disease is familial lipoprotein lipase deficiency.